| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FBXO6 |
| Uniprot No | Q9NRD1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-293aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMDAPHSK AALDSINELP ENILLELFTH VPARQLLLNC RLVCSLWRDL IDLMTLWKRK CLREGFITKD WDQPVADWKI FYFLRSLHRN LLRNPCAEED MFAWQIDFNG GDRWKVESLP GAHGTDFPDP KVKKYFVTSY EMCLKSQLVD LVAEGYWEEL LDTFRPDIVV KDWFAARADC GCTYQLKVQL ASADYFVLAS FEPPPVTIQQ WNNATWTEVS YTFSDYPRGV RYILFQHGGR DTQYWAGWYG PRVTNSSIVV SPKMTRNQAS SEAQPGQKHG QEEAAQSPYR AVVQIF |
| 预测分子量 | 36 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FBXO6重组蛋白的模拟参考文献示例(注：文献信息为示例，非真实存在，仅供格式参考)：
---
1. **文献名称**：*FBXO6 mediates glycoprotein recognition in ER-associated degradation via a novel sugar-binding domain*
**作者**：Chen L, et al.
**摘要**：本研究通过重组表达FBXO6蛋白，揭示了其C端结构域特异性识别高甘露糖型N-聚糖的机制，并证明其在内质网相关降解(ERAD)中靶向错误折叠糖蛋白进行泛素化。
2. **文献名称**：*Structural basis of SCFFBXO6-substrate interaction in cancer cell proliferation*
**作者**：Wang Y, et al.
**摘要**：利用重组FBXO6蛋白的晶体结构分析，阐明了其与底物PDCD4的结合模式，表明FBXO6通过促进PDCD4降解调控结直肠癌细胞增殖。
3. **文献名称**：*FBXO6 regulates α-synuclein clearance by ubiquitinating lysosomal enzymes*
**作者**：Kim S, et al.
**摘要**：通过体外重组实验，发现FBXO6介导溶酶体酶LAMP2A的泛素化，影响α-synuclein的清除，为帕金森病病理机制提供新视角。
---
如需真实文献，建议在PubMed或Web of Science中检索关键词“FBXO6 recombinant protein”或“FBXO6 ubiquitination”。实际研究中，FBXO6常与糖蛋白质量控制、肿瘤耐药性及神经退行性疾病相关。
FBXO6 is a member of the F-box protein family, characterized by a conserved F-box domain that enables interaction with Skp1. a core component of the SCF (Skp1-Cul1-F-box) E3 ubiquitin ligase complex. As an adaptor protein, FBXO6 plays a critical role in substrate recognition for ubiquitination, a process essential for targeted protein degradation via the ubiquitin-proteasome system (UPS). It is particularly notable for its involvement in endoplasmic reticulum-associated degradation (ERAD), where it facilitates the ubiquitination of misfolded glycoproteins by recognizing high-mannose oligosaccharides through its lectin-like activity. This function links FBXO6 to cellular quality control and stress response mechanisms.
The recombinant FBXO6 protein is engineered for research applications, often expressed in systems like *E. coli* or mammalian cells, with tags (e.g., His, GST) for purification and detection. Its structure typically includes the F-box domain for Skp1 binding and a C-terminal domain for substrate interaction. Studies implicate FBXO6 in diverse physiological and pathological processes, including cancer progression, neurodegenerative diseases (e.g., Parkinson’s), and metabolic disorders like diabetes. For example, FBXO6-mediated degradation of Parkin or Ero1α highlights its regulatory roles in mitochondrial homeostasis and oxidative stress.
Researchers utilize recombinant FBXO6 to explore substrate specificity, enzymatic activity, and interactions within the UPS. It also serves as a tool for drug discovery, particularly in diseases linked to protein misfolding or dysregulated ubiquitination. Despite its established roles, ongoing studies aim to clarify tissue-specific functions and post-translational modifications influencing its activity. Overall, FBXO6 exemplifies the intersection of proteostasis and human health, driving interest in its mechanistic and therapeutic potential.
×
